Synthetic lethality precision medicine oncology company pursuing– an emerging class of precision medicine targets.
Synthetic Lethality and Precision Medicine
51 - 200
💰 $80M Post-IPO Equity on 2022-09
11 hours ago
🏢 In-office - San Francisco
⏰ Full Time
🟠 Senior
🛂 H1B Visa Sponsor
August 31
🔴 Lead
💸 Financial Planning and Analysis
August 18
🔄 Hybrid – San Francisco
🔧 QA Engineer (Quality Assurance)
Google Cloud Platform
August 14
🚔 Compliance
July 25
July 17
July 3
🧑⚖️ General Counsel